Table 1. Baseline characteristics of the patients and pathologic outcomes (n=786).
| Variable | Value |
|---|---|
| Age (y) | 64.9±6.6 |
| PSA (ng/mL) | 12.4±12.9 |
| PSA group | |
| <4 | 60 (7.6) |
| ≥4 and <10 | 418 (53.2) |
| ≥10 and <20 | 200 (25.4) |
| ≥20 | 108 (13.7) |
| Clinical T stage | |
| ≤T1c | 186 (23.7) |
| T2a, T2b | 580 (73.8) |
| T2c | 20 (2.5) |
| ISUP grade group | |
| I | 372 (47.3) |
| II | 122 (15.5) |
| III | 115 (14.6) |
| IV–V | 177 (22.5) |
| D'Amico risk classification | |
| Low | 266 (33.8) |
| Intermediate | 274 (34.9) |
| High | 246 (31.3) |
| PLND | |
| None | 413 (52.5) |
| Yes | 373 (47.5) |
| Nerve saving | |
| None | 374 (47.6) |
| Unilateral | 115 (14.6) |
| Bilateral | 297 (37.8) |
| Pathologic ISUP grade group | |
| I | 209 (26.6) |
| II | 295 (37.5) |
| III | 153 (19.5) |
| IV–V | 119 (15.1) |
| Vanishing | 10 (1.3) |
| Pathologic outcomes | |
| T stage | |
| Vanishing | 10 (1.3) |
| T2a,b | 160 (20.4) |
| T2c | 309 (39.3) |
| T3a | 197 (25.1) |
| T3b | 109 (13.9) |
| T4 | 1 (0.1) |
| EPE | 268 (34.1) |
| SVI | 109 (13.9) |
| Surgical margin | 291 (37.0) |
| N stage | |
| N0 | 359 (45.7) |
| N1 | 22 (2.8) |
| Nx | 405 (51.5) |
Values are presented as mean±standard deviation or number (%).
PSA, prostate-specific antigen; ISUP, International Society of Urological Pathology; PLND, pelvic lymph node dissection; EPE, extraprostatic extension; SVI, seminal vesicle invasion.